Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 1/20 | 0.59 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | MPO | P05164 | 7/20 | 0.47 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 3/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21546056 | 0.79 | CAPN1 (0.56) | CAPN1CAPN2KMT2AMEN1NPC1 | |
| SCHEMBL29404592 | 0.79 | CAPN1 (0.56) | CAPN1CAPN2KMT2AMEN1NPC1 | |
| SCHEMBL21546057 | 0.79 | CAPN1 (0.56) | CAPN1CAPN2KMT2AMEN1NPC1 | |
| SCHEMBL19243047 | 0.79 | CAPN1 (0.56) | CAPN1CAPN2KMT2AMEN1NPC1 | |
| SCHEMBL3741787 | 0.78 | KMT2A (0.56) | CAPN1CAPN2KMT2AMEN1NPC1 | |
| SCHEMBL28701110 | 0.78 | CAPN1 (0.59) | CAPN1CAPN2KMT2AMEN1NPC1 | |
| SCHEMBL25001258 | 0.77 | APP (0.58) | KMT2AMEN1NPC1RAB9AKDM4E | |
| SCHEMBL13957453 | 0.76 | CAPN1 (0.56) | CAPN1CAPN2KMT2AMEN1NPC1 | |
| SCHEMBL27640766 | 0.76 | MPO (0.56) | CAPN1CAPN2KMT2AMEN1NPC1 | |
| SCHEMBL28933481 | 0.75 | CAPN1 (0.52) | CAPN1CAPN2KMT2AMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647724-B2 | Selective estrogen receptor degraders and uses thereof | INVENTISBIO INC. (KY) | 2020-05-12 | — | — | US | disclosed |
| US-20200040001-A1 | SELECTIVE ESTROGEN RECEPTOR DEGRADERS AND USES THEREOF | INVENTISBIO LLC | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647724-B2 | Selective estrogen receptor degraders and uses thereof | ESR1, ESRRA, ESR2 | CAPN1 948/4885CAPN2 790/4885KMT2A 1662/4885 |
| US-20200040001-A1 | SELECTIVE ESTROGEN RECEPTOR DEGRADERS AND USES THEREOF | ESR1, ESRRA, ESR2 | CAPN1 948/4885CAPN2 790/4885KMT2A 1662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.